Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Research output: Contribution to journalReviewResearchpeer-review

  1. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hypozincaemia is associated with severity of aneurysmal subarachnoid haemorrhage: a retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Robert A Hegele
  • Jan Borén
  • Henry N Ginsberg
  • Marcello Arca
  • Maurizio Averna
  • Christoph J Binder
  • Laura Calabresi
  • M John Chapman
  • Marina Cuchel
  • Arnold von Eckardstein
  • Ruth Frikke-Schmidt
  • Daniel Gaudet
  • G Kees Hovingh
  • Florian Kronenberg
  • Dieter Lütjohann
  • Klaus G Parhofer
  • Frederick J Raal
  • Kausik K Ray
  • Alan T Remaley
  • Jane K Stock
  • Erik S Stroes
  • Lale Tokgözoğlu
  • Alberico L Catapano
View graph of relations

Genome sequencing and gene-based therapies appear poised to advance the management of rare lipoprotein disorders and associated dyslipidaemias. However, in practice, underdiagnosis and undertreatment of these disorders are common, in large part due to interindividual variability in the genetic causes and phenotypic presentation of these conditions. To address these challenges, the European Atherosclerosis Society formed a task force to provide practical clinical guidance focusing on patients with extreme concentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density lipoprotein cholesterol. The task force also recognises the scarcity of quality information regarding the prevalence and outcomes of these conditions. Collaborative registries are needed to improve health policy for the care of patients with rare dyslipidaemias.

Original languageEnglish
JournalThe Lancet Diabetes and Endocrinology
Issue number1
Pages (from-to)50-67
Number of pages18
Publication statusPublished - Jan 2020

ID: 59943136